ADR,SEQ,PT,HLT,HLGT,SOC_ABBREV,FATAL_YN
1,1,Aplastic anaemia,Marrow depression and hypoplastic anaemias,Anaemias nonhaemolytic and marrow depression,Blood,N
2,1,Aplastic anaemia,Marrow depression and hypoplastic anaemias,Anaemias nonhaemolytic and marrow depression,Blood,Y
3,1,Vomiting,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
4,1,Vomiting,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
5,1,Vomiting,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
6,1,Giant cell arteritis,Arterial infections and inflammations,Vascular infections and inflammations,Vasc,N
7,1,Thrombophlebitis,Peripheral embolism and thrombosis,Embolism and thrombosis,Vasc,N
8,1,Agitation,Anxiety symptoms,Anxiety disorders and symptoms,Psych,N
9,1,Oesophageal carcinoma,Oesophageal neoplasms malignant,Gastrointestinal neoplasms malignant and unspecified,Neopl,N
10,1,Phlebitis deep,Phlebitis NEC,Vascular infections and inflammations,Vasc,N
11,1,Sensory loss,Sensory abnormalities NEC,Neurological disorders NEC,Nerv,N
12,1,Pulmonary veno-occlusive disease,Vascular pulmonary disorders NEC,Pulmonary vascular disorders,Resp,N
13,1,Cardiopulmonary failure,Heart failures NEC,Heart failures,Card,Y
13,2,Pulmonary hypertension,Pulmonary hypertensions,Pulmonary vascular disorders,Resp,N
13,3,Pulmonary veno-occlusive disease,Vascular pulmonary disorders NEC,Pulmonary vascular disorders,Resp,N
14,1,Cardiopulmonary failure,Heart failures NEC,Heart failures,Card,Y
14,2,Pulmonary hypertension,Pulmonary hypertensions,Pulmonary vascular disorders,Resp,N
15,1,Foetal anaemia,Anaemias NEC,Anaemias nonhaemolytic and marrow depression,Blood,N
15,2,Maternal exposure timing unspecified,"Exposures associated with pregnancy, delivery and lactation","Exposures, chemical injuries and poisoning",Inj&P,N
15,3,Premature baby,Gestational age and weight conditions,Neonatal and perinatal conditions,Preg,N
16,1,Dermatitis,Dermatitis and eczema,Epidermal and dermal conditions,Skin,N
16,2,Product supply issue,Product supply and availability issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
16,3,Skin reaction,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
16,4,Therapy interrupted,Therapeutic procedures NEC,Therapeutic procedures and supportive care NEC,Surg,N
17,1,Condition aggravated,General signs and symptoms NEC,General system disorders NEC,Genrl,N
18,1,Application site reaction,Application site reactions,Administration site reactions,Genrl,N
18,2,Application site ulcer,Application site reactions,Administration site reactions,Genrl,N
18,3,Skin ulcer haemorrhage,Skin and subcutaneous tissue ulcerations,Skin and subcutaneous tissue disorders NEC,Skin,N
19,1,Blister,Bullous conditions,Epidermal and dermal conditions,Skin,N
19,2,Skin burning sensation,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
20,1,Application site pain,Application site reactions,Administration site reactions,Genrl,N
20,2,Application site swelling,Application site reactions,Administration site reactions,Genrl,N
20,3,Erythema,Erythemas,Epidermal and dermal conditions,Skin,N
20,4,Inappropriate schedule of product administration,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
20,5,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
20,6,Skin lesion,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
21,1,Application site vesicles,Application site reactions,Administration site reactions,Genrl,N
22,1,Blister,Bullous conditions,Epidermal and dermal conditions,Skin,N
22,2,Dermatitis,Dermatitis and eczema,Epidermal and dermal conditions,Skin,N
22,3,Dermatitis contact,Dermatitis and eczema,Epidermal and dermal conditions,Skin,N
22,4,Oedema,Oedema NEC,General system disorders NEC,Genrl,N
22,5,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
23,1,Full blood count decreased,Blood counts NEC,Haematology investigations (incl blood groups),Inv,N
23,2,Neutropenia,Neutropenias,White blood cell disorders,Blood,N
23,3,Symptom recurrence,General signs and symptoms NEC,General system disorders NEC,Genrl,N
24,1,Application site dermatitis,Application site reactions,Administration site reactions,Genrl,N
24,2,Seborrhoeic dermatitis,Dermatitis and eczema,Epidermal and dermal conditions,Skin,N
25,1,Dermatitis,Dermatitis and eczema,Epidermal and dermal conditions,Skin,N
25,2,Skin discharge,Skin and subcutaneous conditions NEC,Skin and subcutaneous tissue disorders NEC,Skin,N
25,3,Skin irritation,Dermatitis and eczema,Epidermal and dermal conditions,Skin,N
25,4,Skin ulcer,Skin and subcutaneous tissue ulcerations,Skin and subcutaneous tissue disorders NEC,Skin,N
25,5,Wound secretion,Non-site specific injuries NEC,Injuries NEC,Inj&P,N
26,1,Application site erythema,Application site reactions,Administration site reactions,Genrl,N
26,2,Application site haemorrhage,Application site reactions,Administration site reactions,Genrl,N
26,3,Application site inflammation,Application site reactions,Administration site reactions,Genrl,N
26,4,Application site pruritus,Application site reactions,Administration site reactions,Genrl,N
27,1,Pain of skin,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
27,2,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
27,3,Skin irritation,Dermatitis and eczema,Epidermal and dermal conditions,Skin,N
28,1,Application site pain,Application site reactions,Administration site reactions,Genrl,N
28,2,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
29,1,Death,Death and sudden death,Fatal outcomes,Genrl,Y
30,1,Application site atrophy,Application site reactions,Administration site reactions,Genrl,N
30,2,Application site reaction,Application site reactions,Administration site reactions,Genrl,N
30,3,Application site ulcer,Application site reactions,Administration site reactions,Genrl,N
30,4,Application site vesicles,Application site reactions,Administration site reactions,Genrl,N
30,5,Mouth ulceration,Stomatitis and ulceration,Oral soft tissue conditions,Gastr,N
30,6,Product use issue,"Medication errors, product use errors and issues NEC",Medication errors and other product use errors and issues,Inj&P,N
30,7,Skin texture abnormal,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
31,1,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
31,2,Rash macular,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
32,1,Application site dermatitis,Application site reactions,Administration site reactions,Genrl,N
33,1,Burning sensation,Paraesthesias and dysaesthesias,Neurological disorders NEC,Nerv,N
34,1,Application site erythema,Application site reactions,Administration site reactions,Genrl,N
34,2,Application site inflammation,Application site reactions,Administration site reactions,Genrl,N
34,3,Application site pain,Application site reactions,Administration site reactions,Genrl,N
34,4,Application site pruritus,Application site reactions,Administration site reactions,Genrl,N
34,5,Application site rash,Application site reactions,Administration site reactions,Genrl,N
34,6,Application site vesicles,Application site reactions,Administration site reactions,Genrl,N
34,7,Product complaint,Product quality issues NEC,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
35,1,Blister,Bullous conditions,Epidermal and dermal conditions,Skin,N
35,2,Product complaint,Product quality issues NEC,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
35,3,Skin burning sensation,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
36,1,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
36,2,Pain of skin,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
37,1,Fall,Non-site specific injuries NEC,Injuries NEC,Inj&P,N
37,2,Muscular weakness,Muscle weakness conditions,Muscle disorders,Musc,N
37,3,Product complaint,Product quality issues NEC,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
37,4,Product container issue,Product packaging issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
37,5,Product use issue,"Medication errors, product use errors and issues NEC",Medication errors and other product use errors and issues,Inj&P,N
37,6,Shoulder fracture,Limb fractures and dislocations,Bone and joint injuries,Inj&P,N
38,1,Death,Death and sudden death,Fatal outcomes,Genrl,Y
39,1,Erythema,Erythemas,Epidermal and dermal conditions,Skin,N
39,2,Inappropriate schedule of product administration,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
39,3,Mass,Mass conditions NEC,Tissue disorders NEC,Genrl,N
39,4,Product prescribing issue,Product prescribing errors and issues,Medication errors and other product use errors and issues,Inj&P,N
39,5,Product use issue,"Medication errors, product use errors and issues NEC",Medication errors and other product use errors and issues,Inj&P,N
39,6,Therapy interrupted,Therapeutic procedures NEC,Therapeutic procedures and supportive care NEC,Surg,N
40,1,Condition aggravated,General signs and symptoms NEC,General system disorders NEC,Genrl,N
41,1,Blister,Bullous conditions,Epidermal and dermal conditions,Skin,N
41,2,Erythema,Erythemas,Epidermal and dermal conditions,Skin,N
41,3,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
41,4,Symptom recurrence,General signs and symptoms NEC,General system disorders NEC,Genrl,N
